<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01316861</url>
  </required_header>
  <id_info>
    <org_study_id>EMSAGL0110</org_study_id>
    <nct_id>NCT01316861</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Oral Acarbose Treatment in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Oral Acarbose Treatment in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Purpose of This Study is to Evaluate the Efficacy and Safety of Acarbose in Type 2
      Diabetic Patients Using Two Different Formulations of Acarbose 50mg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:

        -  Multicenter

        -  Phase III

        -  Randomized

        -  Double Blind

        -  Prospective and Comparative

        -  Experiment duration: 105 days

        -  5 visits

        -  Efficacy

        -  Adverse event
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycosylated hemoglobin (HbA1c)</measure>
    <time_frame>Change from baseline to day 98</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease in mean Fasting Plasma Glucose (FPG)</measure>
    <time_frame>Change from baseline to day 14, 28, 42, 70 and 98</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety will be evaluated by the Adverse events occurence</measure>
    <time_frame>Day 105</time_frame>
    <description>Adverse events will be collected and followed in order to evaluate safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>EMS Acarbose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bayer Acarbose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EMS Acarbose</intervention_name>
    <description>EMS Acarbose 50 mg 3 times a day</description>
    <arm_group_label>EMS Acarbose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bayer Acarbose</intervention_name>
    <description>Bayer Acarbose 50 mg 3 times a day</description>
    <arm_group_label>Bayer Acarbose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be able to understand the study procedures agree to participate and give
             written consent.

          -  Diagnosed with type 2 diabetes mellitus (t2dm)b

          -  Female patients of childbearing potential (i.e., ovulating, pre-menopausal, not
             surgically sterile) which agree to use a medically accepted contraceptive regimen for
             the duration of the study.

        Exclusion Criteria:

          -  Pregnancy or risk of pregnancy.

          -  Lactation

          -  Any pathology or past medical condition that can interfere with this protocol

          -  Other conditions deemed reasonable by the medical investigator as to the
             disqualification of the individual from study participation.

          -  Known hypersensitivity / intolerance to acarbose or any of its excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felipe Pinho, MD</last_name>
    <role>Study Director</role>
    <affiliation>EMS S/A</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Marcio Antonio Pereira Clinica</name>
      <address>
        <city>Sao Jose Dos Campos</city>
        <state>SP</state>
        <zip>12.245-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2011</study_first_submitted>
  <study_first_submitted_qc>March 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2011</study_first_posted>
  <last_update_submitted>September 24, 2013</last_update_submitted>
  <last_update_submitted_qc>September 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acarbose</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

